Normoglycaemia in Intensive Care Evaluation and Survival Using Glucose Algorithm Regulation (NICE - SUGAR STUDY)

Summary

The primary aim of the study is to compare the effects of the two blood glucose targets on 90 day all-cause mortality in Intensive Care patients who are predicted on admission to stay in the ICU for at least one full calendar day. The hypothesis is that there is little difference in the relative risk of death between patients assigned a glucose range of 4.5 - 6.0 mmol/L, and those assigned a glucose range of less than 10.0 mmol/L with insulin being infused if blood glucose exceeds 10.0 mmol/L, and adjusted when needed to maintain blood glucose of 8.0 - 10.0 mmol/L.

Conditions

• Hyperglycemia
• Critical Illness

Interventions

OTHER

Intensive Insulin Therapy

Maintain blood glucose 4.5 - 6.o mmol/L

OTHER

Conventional Insulin therapy

Maintain blood glucose 8-10mmol/L

Sponsors & Collaborators

• Australian and New Zealand Intensive Care Society Clinical Trials Group

  collaborator NETWORK

• Canadian Critical Care Trials Group

  collaborator OTHER

• National Health and Medical Research Council, Australia

  collaborator OTHER

• Health Research Council, New Zealand

  collaborator OTHER

• University of British Columbia

  collaborator OTHER

• The George Institute

  lead OTHER

Principal Investigators

• Simon Finfer, MBBS · Royal North Shore Hospital

• John Myburgh, MBBS · St. George Hospital, Sydney

• Rinaldo Bellomo, MBBS · Austin Hospital, Melbourne Australia

• Imogen Mitchell, MBBS · The Canberra Hospital, ACT

• Colin McArthur, MBBS · Auckland Hospital, New Zealand

• Robyn Norton, Prof. · The George Institute

• Suzanne McEvoy, MBBS · The George Institute

• Leonie J Crampton, RN; CNS · The George Institute

• Julie Potter, RN · Royal North Shore Hospital

• Vinay Dhingra, MBBS · Vancouver General Hospital

• Deborah Cook, MBBS · St. Joseph's Hospital, Ontario

• Paul Hebert, MBBS · The Ottawa Hospital

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2005-04-30

Primary Completion

2008-11-30

Completion

2008-11-30

Countries

• Australia

Study Locations